CLINICAL_TRIALS
trial_result
· 2021-12-14
Clinical Trial Update: A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model. [Phase 3]
Summary
Phase 3 clinical trial evaluating bilastine ophthalmic solution 0.6% in an allergic conjunctivitis model has completed, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Faes Farma, S.A. | Conditions: Allergic Conjunctivitis | Phase 3 | Status: COMPLETED | Results posted: 2021-12-14